Department of Pediatrics, The Third Xiangya Hosptial of Central South University, Changsha, Hunan, China.
J Appl Microbiol. 2022 Aug;133(2):908-921. doi: 10.1111/jam.15602. Epub 2022 May 16.
Bronchopulmonary dysplasia (BPD) is a common respiratory disease in newborns; however, there is no effective treatment. We aimed to investigate the effects of the potential probiotics Limosilactobacillus reuteri and Bifidobacterium bifidum on BPD using 16S rDNA sequencing and metabolomics methods.
Faecal samples were collected from 10 BPD patients and 10 healthy subjects. 16S rDNA sequencing results showed that microbial diversity was decreased and compositions were affected in BPD. Escherichia-Shigella and Clostridium_sensu_stricto_1 were increased in the BPD group, and Enterobacteriaceae, Megamonas, Blautia, Lactobacillus (Limosilactobacillus), [Eubacterium]_coprostanoligenes_group, Phascolarctobacterium and Bifidobacterium were reduced. Metabolomics analysis identified 129 differentiated metabolites that were changed in BPD patients, and they were associated with a preference for carbohydrate metabolism in translation and metabolism during genetic information processing. Correlation analysis revealed a remarkable relationship between gut microbiota and metabolites. Subsequently, a BPD cell model was constructed to test the effect of the potential probiotics. Cell function experiments verified that treatment with the potential probiotics L. reuteri and B. bifidum promoted proliferation and inhibited apoptosis of hyperoxia-induced MLE-12 cells. In addition, treatment with the potential probiotics L. reuteri and B. bifidum reduced inflammation and oxidative stress damage.
Treatment with the potential probiotics L. reuteri and B. bifidum could alleviate BPD and reduce inflammation and oxidative stress damage.
This study was the first to report positive roles for the potential probiotics L. reuteri and B. bifidum in BPD. The potential probiotics L. reuteri and B. bifidum were shown to reduce inflammation and oxidative stress damage in BPD. This study provided new insights on the pathogenesis and treatment of BPD.
支气管肺发育不良（BPD）是新生儿常见的呼吸系统疾病，但目前尚无有效的治疗方法。本研究旨在通过 16S rDNA 测序和代谢组学方法探讨潜在益生菌罗伊氏乳杆菌和双歧杆菌对 BPD 的影响。
收集 10 例 BPD 患儿和 10 例健康对照的粪便标本。16S rDNA 测序结果显示，BPD 患儿的微生物多样性降低，菌群组成发生改变。BPD 组中埃希氏菌-志贺氏菌属和严格梭菌属 1 增加，肠杆菌科、巨单胞菌属、布劳特氏菌属、乳杆菌属（罗伊氏乳杆菌）、真杆菌属/丁酸弧菌属、粪球菌属和双歧杆菌属减少。代谢组学分析发现 129 种差异代谢物在 BPD 患者中发生变化，这些代谢物与翻译过程中碳水化合物代谢和遗传信息处理过程中的代谢偏好有关。相关性分析显示肠道微生物群与代谢物之间存在显著关系。随后构建 BPD 细胞模型以测试潜在益生菌的作用。细胞功能实验验证了潜在益生菌罗伊氏乳杆菌和双歧杆菌的治疗作用可促进高氧诱导的 MLE-12 细胞增殖并抑制细胞凋亡。此外，潜在益生菌罗伊氏乳杆菌和双歧杆菌的治疗作用可减轻炎症和氧化应激损伤。
潜在益生菌罗伊氏乳杆菌和双歧杆菌的治疗作用可缓解 BPD，并减轻炎症和氧化应激损伤。
本研究首次报道了潜在益生菌罗伊氏乳杆菌和双歧杆菌在 BPD 中的积极作用。潜在益生菌罗伊氏乳杆菌和双歧杆菌可减轻 BPD 中的炎症和氧化应激损伤。本研究为 BPD 的发病机制和治疗提供了新的见解。
